We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy.
- Authors
Stephenson, Andrew J.; Shariat, Shahrokh F.; Zelefsky, Michael J.; Kattan, Michael W.; Butler, E. Brian; Teh, Bin S.; Klein, Eric A.; Kupelian, Patrick A.; Roehrborn, Claus G.; Pistenmaa, David A.; Pacholke, Heather D.; Liauw, Stanley L.; Katz, Matthew S.; Leibel, Steven A.; Scardino, Peter T.; Slawin, Kevin M.
- Abstract
Context: Salvage radiotherapy may potentially cure patients with disease recurrence after radical prostatectomy, but previous evidence has suggested that it is ineffective in patients at the highest risk of metastatic disease progression. Objective: To delineate patients who may benefit from salvage radiotherapy for prostate cancer recurrence by identifying variables associated with a durable response. Design, Setting, and Patients: Retrospective review of a cohort of 501 patients at 5 US academic tertiary referral centers who received salvage radiotherapy between June 1987 and November 2002 for detectable and increasing prostate-specific antigen (PSA) levels after radical prostatectomy. Main Outcome Measure: Disease progression after salvage radiotherapy, defined as a serum PSA value ≥0.1 ng/mL above the postradiotherapy PSA nadir confirmed by a second PSA measurement that was higher than the first by any amount, by a continued increase in PSA level after treatment, or by the initiation of androgen deprivation therapy after treatment. Results: Over a median follow-up of 45 months, 250 patients (50%) experienced disease progression after treatment, 49 (10%) developed distant metastases, 20 (4%) died from prostate cancer, and 21 (4%) died from other or unknown causes. The 4-year progression-free probability (PFP) was 45% (95% confidence interval [CI], 40%-50%). By multivariable analysis, predictors of progression were Gleason score of 8 to 10 (hazard ratio [HR], 2.6; 95% CI, 1.7-4.1; P<.001), preradiotherapy PSA level greater than 2.0 ng/mL (HR, 2.3; 95% CI, 1.7-3.2; P<.001), negative surgical margins (HR, 1.9; 95% CI, 1.4-2.5; P<.001), PSA doubling time (PSADT) of 10 months or less (HR, 1.7; 95% CI, 1.2-2.2; P = .001), and seminal vesicle invasion (HR, 1.4; 95% CI, 1.1-1.9; P = .02). Patients with no adverse features had a 4-year PFP of 77% (95% CI, 64%-91%). When treatment was given for early recurrence (PSA level ≤2.0 ng/mL), patients with Gleas...
- Subjects
RADIOTHERAPY; PROSTATE cancer; CANCER treatment; DISEASES; HOSPITAL radiological services
- Publication
JAMA: Journal of the American Medical Association, 2004, Vol 291, Issue 11, p1325
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.291.11.1325